Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0008991046
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG002NCK5M5
ADMA
ADMA Biologics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
ADMA Biologics Inc
ISIN
US0008991046
TICKER
ADMA
MIC
XNAS
REUTERS
ADMA.OQ
BLOOMBERG
ADMA US
Fri, 12.06.2026       ADMA Biologics
US0008991046

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). ADMA investors have until August 10, 2026 to file a le...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 12, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       ADMA Biologics
US0008991046

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (“ADMA” or “the Company”) (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investor...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       ADMA Biologics
US0008991046

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) securities during the period of August 9, 2024 through March 25, 2026, inclusive (“the Class Period”).If you suffered a loss on your ADMA investments, you have unti...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       ADMA Biologics
US0008991046

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (NasdaqGM: ADMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics who were adverse...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. T...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       ADMA Biologics
US0008991046

SAN DIEGO, June 11, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics clas...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       ADMA Biologics
US0008991046

Boston, Massachusetts--(Newsfile Corp. - June 11, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its executives. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover th...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       ADMA Biologics
US0008991046

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). ADMA investors have until August 10, 2026 to file a lead plaintiff motion.IF YOU...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 11.06.2026       ADMA Biologics
US0008991046

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in ADMA...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       ADMA Biologics
US0008991046

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the trea...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       ADMA Biologics
US0008991046

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for ADMA Biologics investors under the federal se...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sun, 07.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       ADMA Biologics
US0008991046

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sat, 23.05.2026       ADMA Biologics
US0008991046

NEW YORK, May 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allega...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - May 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       ADMA Biologics
US0008991046

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 15.05.2026       ADMA Biologics
US0008991046

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.05.2026       ADMA Biologics
US0008991046

NEW YORK, May 12, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allega...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.05.2026       ADMA Biologics
US0008991046

Boston, Massachusetts--(Newsfile Corp. - May 11, 2026) - Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit htt...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.05.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - May 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the inves...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.05.2026       ADMA Biologics
US0008991046

NEW YORK, May 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from al...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       ADMA Biologics
US0008991046

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       ADMA Biologics
US0008991046

Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA). On May 6, 2026, ADMA Biologics reported that "[b]eginning in the second half of 2025 and continuing into the first quarter o...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       ADMA Biologics
US0008991046

Boston, Massachusetts--(Newsfile Corp. - May 7, 2026) - Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit http...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       ADMA Biologics
US0008991046

NEW YORK, May 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from al...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       ADMA Biologics
US0008991046

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.04.2026       ADMA Biologics
US0008991046

NEW YORK, April 25, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the in...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ADMA Biologics
US0008991046

ADMA Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ADMA Biologics
US0008991046

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON ADMA BIOLOGICS, INC. (ADMA), CLIC...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ADMA Biologics
US0008991046

NEW YORK, April 20, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ADMA Biologics
US0008991046

Law Offices of Howard G. Smith continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ADMA BIOLOGICS, INC. (ADMA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALL...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       ADMA Biologics
US0008991046

The Law Offices of Frank R. Cruz continues its investigation of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON ADMA BIOLOGICS, INC. (ADMA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       ADMA Biologics
US0008991046

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       ADMA Biologics
US0008991046

NEW YORK, April 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       ADMA Biologics
US0008991046

ADMA Biologics guided 2026 revenue to at least $635 million -- built on a 2025 revenue base a short-seller report alleges was inflated by as much as 23 percentage points.NEW YORK, April 15, 2026 /PRNewswire/ -- ADMA Biologics (NASDAQ: ADMA) raised its 2026 total revenue guidance to at at least $635 million in its Q4 release on February 25, 2026, u...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       ADMA Biologics
US0008991046

SAN FRANCISCO, April 14, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported."...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ADMA Biologics
US0008991046

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ADMA Biologics
US0008991046

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA Biologics, Inc.") concerning potential violations of the federal securities laws.On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 mill...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ADMA Biologics
US0008991046

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       ADMA Biologics
US0008991046

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       ADMA Biologics
US0008991046

The law firm of Kirby McInerney LLP continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ADMA Biologics
US0008991046

ADMA Biologics guided 2026 revenue to at least $635 million -- built on a 2025 revenue base a short-seller report alleges was inflated by as much as 23 percentage points.NEW YORK, April 1, 2026 /PRNewswire/ -- ADMA Biologics (NASDAQ: ADMA) raised its 2026 total revenue guidance to at at least $635 million in its Q4 release on February 25, 2026, up...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ADMA Biologics
US0008991046

BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.NEW YORK, March 31, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential viol...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       ADMA Biologics
US0008991046

SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported."...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink